Viridian is positioned to break Tepezza’s TED monopoly with a faster IV regimen now—and a potentially market-expanding at-home SC franchise next—creating asymmetric upside into 2026’s binary catalysts.
Overview
Viridian Therapeutics (VRDN) is a late-stage biopharma approaching commercialization, focused on serious, rare autoimmune disease—primarily Thyroid Eye Disease (TED), where current treatment is dominated by Amgen’s Tepezza. TED causes inflammatory orbital tissue expansion leading to proptosis and diplopia, producing functional and psychosocial impairment; the market is established yet underpenetrated due to treatment burden. Viridian’s near-term value is anchored by two IGF-1R monoclonal antibodies: IV veligrotug (VRDN-001), now under FDA Priority Review with a June 30, 2026 PDUFA date, and SC elegrobart (VRDN-003) completing global Phase 3 trials with key data expected in Q1/Q2 2026. The company is pre-commercial in its core markets, with 2025 revenue ($70.8M) largely from a Kissei Japan licensing upfront payment, while the future revenue model depends on U.S./EU approvals and launch execution. Viridian’s go-to-market is concentrated on ~2,000 high-volume U.S. TED prescribers. Beyond TED, it is diversifying into FcRn inhibitors (VRDN-006/008) and a TSHR inhibitor, aiming to evolve into a broader immunology platform and reduce single-asset risk.